This review aims to provide a comprehensive synthesis of the current understanding of immunotherapeutic biomarkers in ESCC, with particular emphasis on PD-L1, the TIME, tumor cell–related molecular features, and their clinical implications in guiding immunotherapy strategies. Here, CD274 is linked to neoplasm.